Physician profile
Robert Satterfield
NPI 1467416347
$2,108.30
in general payments reported to CMS, 2019-2025
22 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.61 · 2021: $158 · 2022: $607 · 2023: $301 · 2024: $684 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $644.10 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $254.39 | 2023-2025 | Evenity, Repatha, Otezla |
| Dexcom, INC. | $153.43 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $142.95 | 2021 | |
| Lilly USA, LLC | $128.40 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Harmony Biosciences LLC | $125.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $123.06 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $120.86 | 2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals Lp | $84.55 | 2023-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $51.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.59 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $36.21 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $27.65 | 2024 | Greenlight Xps |
| Phathom Pharmaceuticals, INC. | $26.00 | 2024 | Voquezna |
| Biogen, INC. | $24.13 | 2025 | Spinraza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $22.00 | 2024 | |
| Sanofi Pasteur INC. | $21.10 | 2024 | |
| Pfizer INC. | $19.89 | 2024 | |
| Resmed Corp | $18.10 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.40 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $15.37 | 2021 | |
| Kci USA, INC. | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Satterfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.